Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication

Morgan Murphrey; Reid Alexander Waldman; Timothy Durso; Jane M Grant-Kels

doi:10.1016/j.jaad.2021.09.051

Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication

J Am Acad Dermatol. 2022 Jan;86(1):42-43. doi: 10.1016/j.jaad.2021.09.051. Epub 2021 Sep 30.

Authors

Morgan Murphrey¹, Reid Alexander Waldman², Timothy Durso³, Jane M Grant-Kels⁴

Affiliations

¹ Department of Dermatology, University of California, Davis, California.
² Dermatology Associates of Glastonbury, Glastonbury, Connecticut. Electronic address: rawaldmanmd@gmail.com.
³ Department of Dermatology at Joint Base Andrews, Joint Base Andrews, Maryland.
⁴ Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut.

PMID: 34600033
DOI: 10.1016/j.jaad.2021.09.051

No abstract available

Keywords: Janus kinase inhibitor; abrocitinib; alopecia areata; atopic dermatitis; baricitinib; psoriasis; ruxolitinib; tofacitinib; upadacitinib.

Publication types

Editorial

MeSH terms

Alopecia Areata*
Communication
Humans
Janus Kinase 1
Janus Kinase Inhibitors* / adverse effects
Janus Kinases
United States
United States Food and Drug Administration

Substances

Janus Kinase Inhibitors
Janus Kinase 1
Janus Kinases